TEL
AVIV, Israel, Feb. 14,
2024 /PRNewswire/ -- Chemomab Therapeutics Ltd.
(Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company
developing innovative therapeutics for fibro-inflammatory diseases
with high unmet need, today announced the company will issue a
press release reporting its fourth quarter and full year 2023
financial results and providing a business update on March 7, 2024, at 7:00 am
Eastern Time.
Investors who would like to discuss the financial results or
business update after the press release is issued are invited to
contact the company at IR@chemomab.com.
About Chemomab Therapeutics Ltd.
Chemomab is a
clinical stage biotechnology company developing innovative
therapeutics for fibro-inflammatory diseases with high unmet need.
Based on the unique and pivotal role of CCL24 in promoting fibrosis
and inflammation, Chemomab developed CM-101, a monoclonal antibody
that neutralizes CCL24 activity. In clinical and preclinical
studies, CM-101 appears safe, with the potential to treat multiple
severe and life-threatening fibro-inflammatory diseases.
Chemomab has reported positive results from three clinical trials
of CM-101 in patients, including a Phase 2a liver fibrosis trial in
NASH patients and an investigator-initiated study in patients with
severe lung injury. A Phase 2 trial in primary sclerosing
cholangitis has completed patient enrollment, with topline data
expected midyear 2024. Chemomab's CM-101 program for the treatment
of systemic sclerosis is Phase 2-ready. For more information about
Chemomab, visit chemomab.com.
Contacts:
Media and Investors:
Barbara Lindheim
Consulting Vice President, Investor & Public Relations,
Strategic Communications
Phone: +1 917-355-9234
barbara.lindheim@chemomab.com
IR@chemomab.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/chemomab-therapeutics-to-report-fourth-quarter-and-full-year-2023-financial-results-and-provide-a-business-update-302061454.html
SOURCE Chemomab Therapeutics Ltd